Evidence map›Paper›PMID 37047662›Full record

ArticleInternational journal of molecular sciences2023

Neutrophil Extracellular Traps and Platelet Activation for Identifying Severe Episodes and Clinical Trajectories in COVID-19.

Paula González-Jiménez, Raúl Méndez, Ana Latorre, Mónica Piqueras, María Nieves Balaguer-Cartagena, Antonio Moscardó, Ricardo Alonso, David Hervás, Soledad Reyes, Rosario Menéndez

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Paula González-JiménezPneumology Department, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.ORCID 0000-0003-3386-5230
Raúl MéndezPneumology Department, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.ORCID 0000-0001-6300-9836
Ana LatorreRespiratory Infections, Health Research Institute La Fe, 46026 Valencia, Spain.
Mónica PiquerasMedicine Department, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0002-3329-766X
María Nieves Balaguer-CartagenaPneumology Department, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.
Antonio MoscardóPlatelet Function Unit, Health Research Institute La Fe, 46026 Valencia, Spain.
Ricardo AlonsoLaboratory Department, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.
David HervásData Science, Biostatistics & Bioinformatics, Health Research Institute La Fe, 46026 Valencia, Spain.ORCID 0000-0003-0635-4961
Soledad ReyesPneumology Department, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.
Rosario MenéndezPneumology Department, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.
Hospital Universitari i Politècnic La Fe · ESUniversitat de València · ESLeitat Technological Center · ESUniversitat Politècnica de València · ES

Funding

Generalitat Valenciana GV/2019/081Health Research Institute La Fe 2019-053-1Instituto de Salud Carlos III COV20/00385Instituto de Salud Carlos III JR21/00051Instituto de Salud Carlos III PI17/01421Sociedad Española de Neumología y Cirugía Torácica 133/2016Sociedad Española de Neumología y Cirugía Torácica 39/2015Sociedad Valenciana de Neumología 2017Sociedad Valenciana de Neumología 2018
6 · The paper itself

Abstract

The role of NETs and platelet activation in COVID-19 is scarcely known. We aimed to evaluate the role of NETs (citrullinated histone H3 [CitH3], cell-free DNA [cfDNA]) and platelet activation markers (soluble CD40 ligand [CD40L] and P-selectin) in estimating the hazard of different clinical trajectories in patients with COVID-19. We performed a prospective study of 204 patients, categorized as outpatient, hospitalized and ICU-admitted. A multistate model was designed to estimate probabilities of clinical transitions across varying states, such as emergency department (ED) visit, discharge (outpatient), ward admission, ICU admission and death. Levels of cfDNA, CitH3 and P-selectin were associated with the severity of presentation and analytical parameters. The model showed an increased risk of higher levels of CitH3 and P-selectin for ED-to-ICU transitions (Hazard Ratio [HR]: 1.35 and 1.31, respectively), as well as an elevated risk of higher levels of P-selectin for ward-to-death transitions (HR: 1.09). Elevated levels of CitH3 (HR: 0.90), cfDNA (HR: 0.84) and P-selectin (HR: 0.91) decreased the probability of ward-to-discharge transitions. A similar trend existed for elevated levels of P-selectin and ICU-to-ward transitions (HR 0.40); In conclusion, increased NET and P-selectin levels are associated with more severe episodes and can prove useful in estimating different clinical trajectories.

Indexed as

Cell-Free Nucleic AcidsCOVID-19Extracellular TrapsHistonesHumansPlatelet ActivationProspective StudiesP-SelectinCell-Free Nucleic AcidsHistonesP-SelectinCOVID-19neutrophil extracellular trapsplatelet activationSARS-CoV-2

Identifiers

PMID37047662
PMCPMC10094814
OpenAlexW4362559908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.